Aquestive Therapeutics, Inc. (AQST) Stock Analysis

Aquestive Therapeutics is a specialty pharmaceutical company using proprietary PharmFilm and AdrenaVerse technologies to deliver prescription therapies through buccal and sublingual films. Its current model combines Suboxone contract manufacturing, licensing and royalties, and a developing proprietary portfolio led by Libervant and Anaphylm. The strategic transition hinges on Anaphylm, a non-injectable epinephrine rescue film for severe allergic reactions; a September 17, 2026 NDA resubmission followed FDA-requested packaging and human-factors changes, validated with zero protocol-defined use errors and a reduction in administration time from 46 seconds to 17 seconds. The addressable global epinephrine rescue market is projected at $2.03 billion by 2029, while patent protection extends to at least May 4, 2037. Q2 2026 revenue rose 38% year over year to $13.82 million, beating consensus, and adjusted EBITDA loss narrowed to $5.2 million, though GAAP net loss widened to $22.9 million after an $11.7 million non-cash debt-extinguishment charge. Cash was $98.5 million, with $95 million of additional financing conditional on approval. **The valuation is chiefly a bet on regulatory conversion and commercial adoption, rather than trailing manufacturing earnings.** The report’s probability-weighted five-year target is $13.87 versus a $4.80 baseline, with FDA review timing and AQST-108 progress as near-term catalysts.